Hewlett Packard Option Alert: Jan 16 $20 Calls Sweep (16) near the midpoint: 1427 vs 11671 OI; Earnings 3/6 After Close 

Hewlett Packard Option Alert: Jan 16 $20 Calls Sweep (16) near the midpoint: 1427 @ $3.9 vs 11671 OI; Earnings 3/6 After Close Ref=$21.41

Hewlett Packard Option Alert: Jan 16 $20 Calls at the Ask: 1501 vs 11671 OI; Earnings 3/6 After Close 

Hewlett Packard Option Alert: Jan 16 $20 Calls at the Ask: 1501 @ $3.9 vs 11671 OI; Earnings 3/6 After Close Ref=$21.425

Hewlett Packard Option Alert: Mar, 2026 $18 Puts at the Ask: 4000 vs 0 OI; Earnings 3/6 After Close 

Hewlett Packard Option Alert: Mar, 2026 $18 Puts at the Ask: 4000 @ $1.64 vs 0 OI; Earnings 3/6 After Close Ref=$21.145

Hewlett Packard (NYSE:HPE) 주식

HEWLETT PACKARD ENTERPRISE

Hewlett Packard

Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment; it also has a high-performance computing business. HPE's stated goal is to be a complete edge-to-cloud company. Its portfolio enables hybrid clouds and hyperconverged infrastructure. It uses a primarily outsourced manufacturing model and employs 60,000 people worldwide.

Palo,Alto,,California,,Usa,-,October,5,,2024,-,Blue,

Technicals

Trading Ideas

휴렛 팩커드 엔터프라이즈(NYSE:HPE)의 주식은 수요일 소폭 하락 마감했다. 이는 어제 5% 이상의 상승 이후 발생한 일이다. 이 움직임은 행동주의 펀드 엘리엇 인베스트먼트 매니지먼트가 휴렛에 15억 달러 이상을 투자했다는 소식에 의해 촉발되었다.

오늘의 주식: 휴렛 팩커드의 주식이 저항선을 돌파했을까?

Close,Up,Of,Hewlett,Packard,Enterprise,Logo,And,Sign,On

Equities

Long Ideas

Options

옵션 코너: 휴렛팩커드 엔터프라이즈의 데스 크로스가 반대 지표가 될 수 있는 이유

Affirm Card

Large Cap

News

Movers

AFRM

CVNA

FTAI

MRVL

RDDT

VSCO

지난주 급락한 대형주 10종목 (3월 3일~7일): 벤처 글로벌 몽고DB 삼사라 마벨 휴렛 팩커드 카바나 FTAI 에비에이션 어펌 홀딩스 레딧 앱러빈

어펌·몽고DB·레딧 등 지난주 급락한 대형주 10종목 (3월 3일~7일)

Hewlett Packard Enterprise Company Common Stock

Hewlett Packard Enterprise Co

Hewlett Packard Enterprise Company 7.625% Series C Mandatory Convertible Preferred Stock

Chegg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHGG#NYSE">CHGG</a>) reported quarterly losses of $(0.06) per share. This is a 123.08 percent decrease over earnings of $0.26 per share from the same period last year. The company reported quarterly sales of $121.39 million which beat the analyst consensus estimate of $114.61 million by 5.92 percent. This is a 30.38 percent decrease over sales of $174.35 million the same period last year.

Earnings

Earnings Beats

CHGG

Chegg Q1 Adj. EPS $(0.06) Down From $0.26 YoY, Sales $121.39M Beat $114.61M Estimate

– ATH434 Phase 2 data demonstrated clinically meaningful efficacy on multiple clinical endpoints –
– MSA Atrophy Index (MSAai) enhances MSA diagnosis and monitoring –
– bioMUSE Study shows higher α- synuclein concentration is associated with greater burden of orthostatic symptoms –
MELBOURNE, Australia and SAN FRANCISCO, May 12, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:<a href="https://www.benzinga.com/stock/ATHE#NASDAQ">ATHE</a>) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that several oral and poster presentations related to Alterity's clinical programs in Multiple System Atrophy (MSA) were featured at the 2025 International MSA Congress. The Congress was presented by Mission MSA, a non-profit organization dedicated to improving the quality of life and building hope for people affected by MSA through support services, educational resources, research funding, and community engagement.

Alterity Therapeutics Limited - American Depositary Shares

ATHE

Alterity Therapeutics Presents MSA Research At 2025 International MSA Congress; ATH434 Phase 2 Data Shows Clinically Meaningful Efficacy On Multiple Clinical Endpoints

ZCAR

Zoomcar Names Automotive Veteran Deepankar Tiwari As CEO, Aims To Deepen Market Presence And Enhance User Experience

Needham analyst Charles Shi maintains Silvaco Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVCO#NASDAQ">SVCO</a>) with a Buy and lowers the price target from $19 to $10.

Price Target

Analyst Ratings

SVCO

Needham Maintains Buy on Silvaco Group, Lowers Price Target to $10

The patent application relates to a combination treatment using Clearmind's 5-methoxy-2-aminoindane ("MEAI") and SciSparc's Palmitoylethanolamide for the treatment of cocaine addiction.

Biotech

Health Care

General

CMND

SPRC

SciSparc Announced That Its Collaboration With Clearmind Medicine Has Led To The Publication Of A European Patent Application By The European Patent Office

ACON

Aclarion Adds Texas Back Institute As New CLARITY Trial Site

Gain Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GANX#NASDAQ">GANX</a>) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that a guided poster presentation was made at the International Association of Parkinsonism and Related Disorders (IAPRD) 30th World Congress on Parkinson's Disease and Related Disorders, held May 7th-10th in New York City, NY. The poster outlined new evidence supporting GT-02287's ability to provide a broader neuroprotective effect and potential as a disease-modifying therapy for Parkinson's disease.

GANX

Gain Therapeutics Presents GT-02287 Data Highlighting Neuroprotective Potential As Disease-Modifying Therapy For Parkinson's Disease At IAPRD 2025

<ul>
<li>Presentation Underscores Deep Track's Value Destructive Plan and Inferior Slate of Director Nominees</li>
<li>Urges Stockholders to Vote&nbsp;"FOR"&nbsp;All Four Dynavax Director Nominees on the&nbsp;GOLD&nbsp;Proxy Card Today</li>
</ul>

DVAX

Dynavax Defends Strategic Direction, Highlights Vaccine Leadership And Capital Returns In Proxy Fight With Deep Track

Rosenblatt analyst Chris Brendler maintains Coinbase Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) with a Buy and maintains $260 price target.

COIN

Rosenblatt Maintains Buy on Coinbase Global, Maintains $260 Price Target

Needham analyst Laura Martin reiterates DoubleVerify Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DV#NYSE">DV</a>) with a Buy and maintains $18 price target.

Reiteration

Needham Reiterates Buy on DoubleVerify Holdings, Maintains $18 Price Target

ProMIS Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMN#NASDAQ">PMN</a>) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.12) by 75 percent. This is a 10.53 percent decrease over losses of $(0.19) per share from the same period last year.

Earnings Misses

ProMIS Neurosciences Q1 EPS $(0.21) Misses $(0.12) Estimate

Bertrand Loy to Retire After 13 Years as President and CEO in August 2025; Will Continue to Serve as Executive Chair of the Entegris Board of Directors
David Reeder Will Succeed Loy as President and CEO

ENTG

Entegris Taps Board Member David Reeder As Next CEO; Bertrand Loy To Become Executive Chair

2025 Outlook
The Company reaffirmed its outlook for 2025 revenues and Adjusted EBITDA to be in the range of $3.30&nbsp;billion to $3.45&nbsp;billion and $555&nbsp;million to $565&nbsp;million, respectively.

Guidance

SGRY

Surgery Partners Affirms FY2025 Sales Guidance of $3.30B-$3.45B vs $3.39B Est

SelectQuote (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLQT#NYSE">SLQT</a>) affirms FY2025 sales outlook from $1.50 billion-$1.57 billion to $1.50 billion-$1.57 billion vs $1.50 billion estimate.

SLQT

SelectQuote Affirms FY2025 Sales Guidance of $1.50B-$1.57B vs $1.50B Est

BridgeBio Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBIO#NASDAQ">BBIO</a>) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, announced today that one rapid-fire abstract and two moderated ePosters on the clinical outcomes and quality of life measures provided by acoramidis in variant transthyretin amyloid cardiomyopathy (ATTR-CM) and one moderated ePoster on a post-hoc analysis of the lower incidence rate of atrial fibrillation-related events in patients with ATTR-CM, all from the ATTRibute-CM study will be shared at the Annual Congress of the Heart Failure Association of the ESC (Heart Failure 2025), taking place in Belgrade, Serbia on May 17 - 20, 2025.
In addition to the four abstracts, three moderated ePosters will be shared on the disease progression of ATTR-CM in a real-world setting, a retrospective cohort study on manifestation to diagnosis of ATTR-CM, and data on the cause of death of ATTR-CM patients in the ATTRibute-CM study.

BBIO

BridgeBio To Present ATTRibute-CM Study Findings At Heart Failure 2025 Congress

In today's digital economy, sleek user experiences aren't a luxury, they're a requirement. But for early-stage startups and lean teams, hiring a full-time designer or licensing high-end UX software often feels out of reach. When resources are tight, how do you build a product that doesn't just function, but delights?
The good news: UX on a budget is not only possible, it's often smarter. A wave of lean, iterative practices and accessible tools is helping startups compete with industry giants, creating customer experiences that punch far above their weight.
<h3 class="wp-block-heading">The Hidden Cost of Ignoring UX</h3>
Let's start with the cost of skipping user experience. According to Forrester, every $1 invested in UX brings up to $100 in return. Poor design, on the other hand, can cripple growth causing user frustration, support churn, and damaged brand trust.
Research by the Design Management Institute found that design-driven companies outperformed the S&amp;P 500 by 219% over 10 years. In the startup world, that difference often translates to the ability to secure early traction, or not.
As Benzinga recently reported in a feature on startup execution risks, <a href="https://www.benzinga.com/money/what-is-product-market-fit-definition-examples-and-complete-guide">getting product-market fit wrong</a> is the top reason new businesses fail. UX plays a critical role in validating that fit. You can't afford to treat design like decoration.
<h3 class="wp-block-heading">Step One: Talk to Real Users Without Burning Your Budget</h3>
Great UX begins with understanding your users. But early-stage founders often avoid UX research because they assume it's expensive and time-consuming.
It doesn't have to be.
<ul class="wp-block-list">
<li><a href="https://maze.co/guides/usability-testing/guerrilla/">Guerilla testing</a>, asking for feedback in forums like Indie Hackers or Reddit's r/startups, can quickly uncover friction points.</li>
<li>Tools like Google Forms and <a class="" href="https://www.typeform.com/">Typeform</a> allow you to gather structured feedback at zero cost.</li>
<li>For usability testing, platforms like Lookback and UserTesting offer starter plans and free trials that let you observe users in action, identify confusion, and iterate.</li>
</ul>
According to usability expert<a href="https://www.nngroup.com/articles/why-you-only-need-to-test-with-5-users/"> Jakob Nielsen</a>, even five test users can reveal over 85% of usability problems.
<h3 class="wp-block-heading">Step Two: Prioritize and Simplify</h3>
When funds are tight, you can't afford bloated features or complicated interfaces. Product simplicity isn't just good UX—it's good business.
Startups like Superhuman built their initial growth around a minimalist feature set designed for speed and focus. Their mantra? Build a product people love, not just tolerate.
Start by:
<ul class="wp-block-list">
<li>Identifying your product's "core loop," the key actions users need to take to succeed.</li>
<li>Cutting or postponing any features that distract from that flow.</li>
<li>Using low-code tools like Figma or Framer to prototype and test early.</li>
</ul>
<h3 class="wp-block-heading">Step Three: Use Analytics to Design Smarter, Not Harder</h3>
Quantitative data can supplement qualitative insights to help you prioritize fixes that matter.
For example, platforms like Hotjar or Microsoft Clarity provide heatmaps and session recordings that reveal how users interact with your site. Are they rage-clicking a feature? Getting stuck in onboarding? Leaving at checkout?
By analyzing these patterns, you can fix what's broken before scaling it.
The most successful SaaS companies today treat UX as a core revenue driver. That means using data to continuously refine the journey.
<h3 class="wp-block-heading">Step Four: Leverage No-Code &amp; Subscription-Based Design Help</h3>
Not every startup can afford a full-time designer. But new subscription-based design services and no-code tools are helping teams scale UX without long-term commitments.
<ul class="wp-block-list">
<li>Services like DesignJoy and Penji offer unlimited UX/UI design on flat monthly plans ideal for teams that need quick turnarounds.</li>
<li>Webflow and Bubble let you build pixel-perfect front-ends with no code at all.</li>
<li>For branding and visual consistency, tools like Picsart offer AI-powered design solutions that help you maintain a polished aesthetic without expensive software.</li>
</ul>
If your startup needs quick, visual improvements for your MVP, background removal with Picsart's tool can transform user-submitted images into cleaner, higher-converting visuals in seconds, ideal for e-commerce, resume builders, or personal portfolio apps.
<h3 class="wp-block-heading">Step Five: Mobile-First Isn't Optional</h3>
More than half of global web traffic comes from mobile. A responsive, mobile-friendly design isn't just a UX best practice—it's now the baseline expectation.
Use responsive frameworks like Tailwind CSS or Bootstrap to ensure your app looks great across screen sizes. Test designs on different devices with tools like Responsively or browser dev tools.
A poor mobile experience is often cited as the reason users abandon apps. By getting it right early, startups can dramatically increase engagement, reduce bounce, and improve SEO performance, especially now that Google's Core Web Vitals weigh mobile UX heavily in rankings.
<h3 class="wp-block-heading">Step Six: Use Visual Hierarchy and CTAs Strategically</h3>
A key principle of UX is guiding user behavior through clarity, not clutter. Startups can increase conversions by refining how calls-to-action (CTAs) are placed, styled, and worded.
Here's how:
<ul class="wp-block-list">
<li>Use contrast and white space to make CTAs stand out.</li>
<li>Position your CTA above the fold and again after key value propositions.</li>
<li>Test different copy, e.g., "Try it free" vs. "See it in action."</li>
</ul>
In an e-commerce context, clear product visuals and clean CTA areas are especially critical. That's where tools like background removers come in, making sure your CTAs aren't visually buried under messy or inconsistent image styles.
<h3 class="wp-block-heading">Final Thoughts: Start Lean, Iterate Fast</h3>
UX isn't a stage it's a continuous loop. By starting small, testing early, and iterating often, startups can build experiences that users love, without breaking the bank.
Lean UX methods, combined with accessible design tools and real user feedback, let even cash-strapped startups stand toe-to-toe with industry veterans.
As Harvard Business Review coverage of <a href="https://hbr.org/2013/05/why-the-lean-start-up-changes-everything">early-stage startup strategies</a> highlights, great design and lean operations aren't mutually exclusive; they're a powerful pairing.
So the next time you&#8217;re debating whether UX is worth the investment, remember: it&#8217;s not a cost. It's your fastest path to product-market fit, brand trust, and long-term growth.

Opinion

Startups

UX on a Budget: How Startups Can Build Better UX Without Breaking the Bank

<ul>
<li>HT-KIT dramatically suppresses tumor growth in preclinical models of GIST and systemic&nbsp;mastocytosis.</li>
<li>Treatment shows potent&nbsp;downregulation of oncogenic KIT mutations with no observed systemic toxicity.</li>
<li>IND filing expected early 2026, opening pathway to first-in-human trials.</li>
</ul>
Preclinical Milestones:
<ul>
<li>Over 80% reduction in KIT expression in vitro using cancer cell lines harboring activating KIT mutations.</li>
<li>Significant inhibition of tumor growth in GIST and mast cell tumor animal models following systemic administration of HT-KIT.</li>
<li>No observable off-target toxicity in liver, kidney, or bone marrow, suggesting a favorable safety profile.</li>
</ul>

HOTH

Hoth Therapeutics Announces Preclinical Data For HT-KIT, With IND Filing Expected In Early 2026; Says 'HT-KIT dramatically suppresses tumor growth in preclinical models of GIST and systemic mastocytosis.'

ABEO

Abeona Therapeutics To Sell Priority Review Voucher For $155M Following FDA Approval Of ZEVASKYN

Agenus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>) reported quarterly losses of $(1.03) per share which beat the analyst consensus estimate of $(1.38) by 25.36 percent. This is a 66.12 percent increase over losses of $(3.04) per share from the same period last year. The company reported quarterly sales of $24.07 million which missed the analyst consensus estimate of $26.26 million by 8.34 percent. This is a 14.07 percent decrease over sales of $28.00 million the same period last year.

Date	Put/Call	Strike Price	Exp Date	DTE	Trade Vol	Day Vol	Vol / OI	OI	Trade Type	Sentiment
10:33 AMFeb 18, 2025	CALL	$20.00	Jan 16, 2026	248	5018	1427	43	11671	SWEEP	NEUTRAL
10:08 AMFeb 18, 2025	CALL	$20.00	Jan 16, 2026	248	1008	1501	9	11671	TRADE	BULLISH
12:47 PMFeb 13, 2025	PUT	$18.00	Mar 20, 2026	311	4000	4000	Infinity	0	TRADE	BEARISH

Comments

Hewlett Packard

Unusual Options Activity for

뉴스

파트너 / 기고자

벤징가 글로벌